IFNA1 and neoplasm: Currently, there is growing interest in the use of MoDC differentiated in the presence of GM-CSF and interferon-α (IFNα), since IFNα MoDC have been described to be more potent in cross-presenting antigen [12–14], which would be beneficial for DC-based tumor vaccines.